VYNE Therapeutics Inc. (VYNE) DCF Valuation

VYNE Therapeutics Inc. (VYNE) DCF Valuation
  • ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
  • ✓ Professional Design: Trusted, Industry-Standard Templates
  • ✓ Pre-Built For Quick And Efficient Use
  • ✓ No Expertise Is Needed; Easy To Follow

VYNE Therapeutics Inc. (VYNE) Bundle

DCF model
Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Simplify VYNE Therapeutics Inc. (VYNE) valuation with this customizable DCF Calculator! Featuring real VYNE financials and adjustable forecast inputs, you can test scenarios and uncover VYNE's fair value in minutes.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue .4 21.0 14.8 .5 .4 .4 .3 .3 .3 .3
Revenue Growth, % 0 4638.83 -29.71 -96.77 -11.11 -9.4 -9.4 -9.4 -9.4 -9.4
EBITDA -94.1 -251.1 -38.9 -34.2 -29.3 -.4 -.3 -.3 -.3 -.3
EBITDA, % -21237.7 -1196.09 -263.89 -7174.63 -6900.47 -100 -100 -100 -100 -100
Depreciation .4 .3 .1 .1 .0 .1 .1 .1 .1 .0
Depreciation, % 79.01 1.62 0.73873 15.09 0 19.29 19.29 19.29 19.29 19.29
EBIT -94.4 -251.4 -39.0 -34.3 -29.3 -.4 -.3 -.3 -.3 -.3
EBIT, % -21316.7 -1197.71 -264.63 -7189.73 -6900.47 -100 -100 -100 -100 -100
Total Cash 76.9 58.6 42.3 30.9 93.3 .4 .3 .3 .3 .3
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables .0 15.8 7.6 5.0 .0
Account Receivables, % 0 75.35 51.39 1048.22 0
Inventories 1.4 7.4 7.3 .1 .0 .2 .1 .1 .1 .1
Inventories, % 306.09 35.27 49.41 20.34 0 41 41 41 41 41
Accounts Payable 3.8 4.8 6.5 2.4 1.7 .3 .3 .2 .2 .2
Accounts Payable, % 851.24 22.77 44.12 500.21 391.27 73.38 73.38 73.38 73.38 73.38
Capital Expenditure .0 -.1 .0 .0 .0 .0 .0 .0 .0 .0
Capital Expenditure, % -2.48 -0.53827 0 0 0 -0.60427 -0.60427 -0.60427 -0.60427 -0.60427
Tax Rate, % -2.08 -2.08 -2.08 -2.08 -2.08 -2.08 -2.08 -2.08 -2.08 -2.08
EBITAT -90.3 -251.2 -38.8 -34.3 -29.9 -.4 -.3 -.3 -.3 -.3
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -87.5 -271.8 -28.6 -28.6 -25.5 -2.0 -.3 -.2 -.2 -.2
WACC, % 10.8 10.8 10.8 10.8 10.8 10.8 10.8 10.8 10.8 10.8
PV UFCF
SUM PV UFCF -2.5
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) 0
Terminal Value -2
Present Terminal Value -1
Enterprise Value -4
Net Debt -30
Equity Value 26
Diluted Shares Outstanding, MM 10
Equity Value Per Share 2.58

What You Will Receive

  • Customizable Excel Template: A fully adjustable Excel-based DCF Calculator featuring pre-filled financial data for VYNE Therapeutics Inc. (VYNE).
  • Actual Market Data: Access to historical performance and future projections (highlighted in the yellow cells).
  • Adjustable Forecasts: Modify key assumptions such as revenue growth, EBITDA %, and WACC.
  • Instant Calculations: Quickly observe how your inputs affect VYNE’s valuation.
  • Professional Resource: Designed for investors, CFOs, consultants, and financial analysts.
  • Intuitive Layout: Organized for simplicity and ease of navigation, complete with step-by-step guidance.

Key Features

  • Comprehensive DCF Calculator: Features detailed unlevered and levered DCF valuation models tailored for VYNE Therapeutics Inc. (VYNE).
  • WACC Calculator: Pre-configured Weighted Average Cost of Capital sheet with adjustable inputs specific to VYNE.
  • Customizable Forecast Assumptions: Adjust growth rates, capital expenditures, and discount rates to fit VYNE's financial landscape.
  • Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios relevant to VYNE Therapeutics Inc. (VYNE).
  • Interactive Dashboard and Charts: Visual representations provide a summary of key valuation metrics for straightforward analysis.

How It Works

  1. Step 1: Download the Excel file for VYNE Therapeutics Inc. (VYNE).
  2. Step 2: Review VYNE's pre-filled financial data and forecasts.
  3. Step 3: Modify key inputs such as revenue growth, WACC, and tax rates (highlighted cells).
  4. Step 4: Observe the DCF model update in real-time as you adjust your assumptions.
  5. Step 5: Analyze the results and leverage them for informed investment decisions.

Why Choose VYNE Therapeutics Inc. (VYNE)?

  • Innovative Solutions: Cutting-edge therapies designed to address unmet medical needs.
  • Proven Expertise: A team of experienced professionals dedicated to advancing healthcare.
  • Commitment to Quality: Rigorous research and development processes ensure high standards.
  • Patient-Centric Approach: Focused on improving patient outcomes through targeted treatments.
  • Strong Partnerships: Collaborations with leading institutions to enhance research capabilities.

Who Should Use VYNE Therapeutics Inc. (VYNE)?

  • Investors: Gain insights into innovative therapies and make informed investment choices.
  • Healthcare Analysts: Utilize comprehensive data to evaluate the company's pipeline and market potential.
  • Consultants: Tailor reports and presentations to highlight VYNE's strategic initiatives and growth opportunities.
  • Pharmaceutical Enthusiasts: Expand your knowledge of drug development processes and industry trends.
  • Educators and Students: Leverage real-life case studies of VYNE for discussions in healthcare and business courses.

What the VYNE Template Contains

  • Comprehensive DCF Model: Editable template featuring detailed valuation calculations tailored for VYNE Therapeutics Inc. (VYNE).
  • Real-World Data: VYNE’s historical and projected financials preloaded for in-depth analysis.
  • Customizable Parameters: Adjust WACC, growth rates, and tax assumptions to explore various scenarios.
  • Financial Statements: Complete annual and quarterly breakdowns for enhanced insights into VYNE's performance.
  • Key Ratios: Integrated analysis for profitability, efficiency, and leverage specific to VYNE.
  • Dashboard with Visual Outputs: Charts and tables designed for clear, actionable results regarding VYNE Therapeutics Inc. (VYNE).

No products were found matching.